PD-1 inhibitors may restore the body’s immune system and release T cells, providing benefits for patients with CAEBV and EBV-HLH; however, further clinical trials and mechanistic studies are still needed. This evidence concerns the gene PDCD1 and hemophagocytic syndrome.